Day: September 27, 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

10581-12-1, Tetramethylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

CORM-349 [Me4N][(OC)3Mn(mu-OCOCH3)3Mn(CO)3]; 150 mg (0.436 mmol) of Mn(CO)5(SO3CF3) and 116 mg (0.872 mmol) of [Me4N][acetate] were stirred in 8 ml of dry THF and 2 ml of methanol, under argon at 50-55 C. for 3 hrs. During this time the colour of the solution went a little darker yellow/orange.Following this, the solvent was removed on rotary evaporator to give a yellow/orange semi-solid residue. This was crystallised from DCM/Ether at -18 C. to give a yellow crystalline product (123 mg, 0.232 mmol). Yield was 100%.Based on the preliminary IR data, the product was initially identified as [Me4N][(Mn(CO)4(OAc)2]. However, additional analysis, particularly X ray crystal structure analysis, has revealed that the product has the title structure. Furthermore, mass spectral data also supports a product having more than one Mn atom.Mr=529.21.1H NMR (CD2Cl2): delta(ppm) 2.29 (s, acetate CH3 6H), 3.33 (s, NMe4 12H)13C NMR (CD2Cl2): delta(ppm) 23.55 (acetate CH3), 56.34 (NMe4), 176.15 (CO), 224.20 (CO)17O NMR (CD2Cl2): delta(ppm) 388.6 (CO)IR (CH2Cl2) nu(cm-1): 2027 (s), 1930 (vs)Mass Spec (ES-) (m/z): 455 ([Mn2(CO)6(OAc)3]-); 315 ([Mn2(CO)(OAc)3]- or [Mn2(CO)4(OAc)(OH)2]-); 257 ([Mn(CO)3(OAc)2]-)Elemental: C16H21Mn2NO12 found (calc) C: 36.80 (36.31), H: 4.90 (4.00), N: 3.60 (2.65)The dimeric structure of the anion has been established by x-ray crystallography.

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Patent; Motterlini, Roberto Angelo; Mann, Brian Ernest; Scapens, David Alistair; US2010/105770; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

294-90-6, 1,4,7,10-Tetraazacyclododecane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

N-(tert-Butoxycarbonyloxy)succinimide (2.50 g, 11.62 mmol) inchloroform (30 mL) was added dropwise into the solution of1,4,7,10-tetraazacyclododecane (1.00 g, 5.80 mmol) in CHCl3(50 mL) during 7 h. The reaction mixture was stirred 24 h at roomtemperature and the solvent was removed under reduced pressure. The residue was suspended in aqueous NaOH (3 M, 50 mL) and theaqueous phase was extracted with CHCl3 (3 50 mL). The combinedextracts were dried with K2CO3 and evaporated to drynessto give 1,7-bis(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecane(10) in quantitative yield.1,3,5-Tris(bromomethyl)benzene (7.65 g, 21.62 mmol) was dissolvedin CHCl3 (150 mL) and Na2CO3 (1.71 g, 16.15 mmol) wasadded. Compound 10 (1.08 g, 2.90 mmol) in CHCl3 (50 mL) wasadded dropwise into the reaction mixture during 11 hours at52 C. The reaction mixture was refluxed for 3 days at 62 C,filtrated, and evaporated to dryness. The residue was purified bysilica gel chromatography (40-70% EtOAc in hexane), giving 11 in27% yield (0.722 g). 1H NMR (500 MHz, CDCl3) d 7.33 (s, 6H), 4.45(s, 8H), 3.71 (s, 4H), 3.21-3.57 (m, 8H), 2.55-2.68 (m, 8H), 1.27(s, 18H). 13C NMR (100 MHz, CDCl3) dppm 155.8, 140.8, 138.5,129.9, 128.3, 79.3, 59.5, 55.2, 46.1, 32.9, 28.4. HRMS(ESI): obsd.921.0840 [M+H]+, Calcd. 921.0795 [M+H]+., 294-90-6

The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Laine, Maarit; Loennberg, Tuomas; Helkearo, Mia; Loennberg, Harri; Inorganica Chimica Acta; vol. 452; (2016); p. 111 – 117;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2, Cinchonidine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of 2 or 3 (0.50 mmol), the corresponding acids RCOOH (0.60 mmol),DCC (0.60 mmol), DMAP (0.1 mmol) in dry dichloromethane (15 mL) was stirred atroom temperature. When the reaction was completed, and checked by TLC, the mixturewas filtered to remove urea from the reaction, and the filtrate was diluted bydichloromethane (45 mL). Subsequently, the diluted organic phase was washed bysaturated aqueous NaHCO3 (30 mL), and brine (30 mL), dried over anhydrousNa2SO4, concentrated in vacuo, and purified by CC to give the pure 9R/S-acyloxyderivatives of cinchonidine and cinchonine 5a-j,l-o and 6a,c,e-o [17-19]. The dataof target compounds are shown as follows.

485-71-2, As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Article; Che, Zhi-Ping; Chen, Gen-Qiang; Jiang, Jia; Lin, Xiao-Min; Liu, Sheng-Ming; Sun, Di; Tian, Yue-E; Yang, Jin-Ming; Zhang, Song; Journal of Asian Natural Products Research; (2020);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: The preparation of the homologous series of osmium complexes with alpha diimineligands was modified from previous literature methods [5]. The precursor Os(L)2Cl2 was synthesized by refluxing ammonium hexachloroosmate in a 1:2 M ratio with L = 2,2?-bipyridine (bpy), 1,10-phenanthroline (phen), or bathophenanthroline (dpp) in 10 mL of ethylene glycol under nitrogen for 45 min. After cooling to room temperature, sodiumhydrosulfite (0.17 M) was added to reduce the osmium from Os(IV) to Os(II). Precipitation of Os(bpy)2Cl2,Os(phen)2Cl2, and Os(dpp)2Cl2 was achieved via an ice-bath,and the solid was washed with deionized water and ethylether. Yields were close to 80 %.

1662-01-7, The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Wagner, Amy M.; Strohecker, Sarah A.; Costello, Elizabeth K.; Rood, Jeffrey A.; Kneas, Kristi A.; Journal of Fluorescence; vol. 26; 6; (2016); p. 2271 – 2280;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

554-95-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.554-95-0,Benzene-1,3,5-tricarboxylic acid,as a common compound, the synthetic route is as follows.

General procedure: Reaction of AgNO3 (33.4 mg, 0.2 mmol), pyridazine (pdz) (16.0 mg, 0.2 mmol) and 1,3,5-benzene tricarboxylic (H3btc) (44.2 mg, 0.2 mmol) took place in H2O-DMF (N,N-Dimethylformamide) solvents (6 ml, v/v = 1:1) in the presence of ammonia (0.5 mL, 14 M) under ultrasonic treatment (160 W, 40 kHz,30 min) at 40 C. The resultant colourless solution was allowed slowly to evaporate at room temperature in the dark. The yellow crystals of complex 1 were obtained after several days.The crystals were isolated by filtration and washed by deionized water and ethanol and dried in the air. Yield based on Ag is 88% .Elemental analysis: Anal. Calc. for Ag6C26H14N4O12: C, 25.563; H,1.155; N, 4.586. Found: C, 25.37; H, 1.19; N, 4.65%. Selected IR peaks (cm1): 3283 (s), 2264 (w), 1863 (w), 1614 (s), 1557 (s),1417 (s), 1360 (s), 1099 (m), 1060 (w), 972 (w), 920 (w), 767 (s), 716 (s), 660 (w), 514 (m), 455 (w).

As the paragraph descriping shows that 554-95-0 is playing an increasingly important role.

Reference£º
Article; Wang, Dan-Feng; Zhang, Ting; Dai, Si-Min; Huang, Rong-Bin; Zheng, Lan-Sun; Inorganica Chimica Acta; vol. 423; PART A; (2014); p. 193 – 200;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4392-87-4,4392-87-4, [2,2′-Bipyridine]-6-carboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of H2bpdc, Fe(NO3)2¡¤9H2O and 10 mL H2O was put in a 15-mL Teflon-lined autoclave. After sonication, the mixture was kept under autogenous pressure at 160 C for 3 days and then cooled to room temperature at 10 C h-1.

As the paragraph descriping shows that 4392-87-4 is playing an increasingly important role.

Reference£º
Article; Xie, Jianhui; Zheng, Baocheng; Li, Bing; Transition Metal Chemistry; vol. 44; 5; (2019); p. 425 – 430;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4479-74-7,2,2-Bipyridine-6,6-dicarboxylic Acid,as a common compound, the synthetic route is as follows.

General procedure: A mixture of Tb(NO3)3¡¤6H2O (0.045 g, 0.10 mmol), H2bpdc (0.024 g, 0.10 mmol) in distilled water (10 mL) that adjusted the pH value to 2.5 with 0.5 mol L-1 NaOH aqueous solution. It was then sealed in a 25 mL Teflon reactor and heated at 160 C for 72 h, and then cooled to ambient temperature at a rate of ca.2 C h-1 to give colorless block crystals of 7, yield: 57% based on H2bpdc.

4479-74-7, As the paragraph descriping shows that 4479-74-7 is playing an increasingly important role.

Reference£º
Article; Ren, Ya-Lan; Wang, Fei; Hu, Huai-Ming; Chang, Zhuguo; Yang, Meng-Lin; Xue, Ganglin; Inorganica Chimica Acta; vol. 434; (2015); p. 104 – 112;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787-70-2,[1,1′-Biphenyl]-4,4′-dicarboxylic acid,as a common compound, the synthetic route is as follows.

Weigh 4,4′-biphthalic acid (10.00g, 41.3mmol) and silver sulfate (28.00g, 89.7mmol) into a 500mL double-necked flask, then add 250mL concentrated sulfuric acid and at room temperature Stir, then weigh the iodine element (23.00g, 90.5mmol) and add it to the double-necked flask, and cover the double-necked flask with tin foil for light-shielding treatment. The reaction takes place at room temperature for 1 hour, then the temperature is raised to 80 C, and the reaction is continued for 24 hours . After the reaction was completed, the reaction solution was cooled to room temperature, and the reaction solution in the double-necked flask was poured into 500 mL of ice water, resulting in a large amount of yellow precipitate, and the crude product was obtained by filtration. The above crude product was added to a 500 mL single-necked flask, and 300 mL of methanol was added. After stirring, 5 mL of concentrated sulfuric acid was slowly added dropwise, the temperature was raised to 100 C, the reaction was refluxed for 12 hours, cooled to room temperature, and the organic solvent was distilled off under reduced pressure. Saturated brine, and extracted three times with 500 mL of dichloromethane. The organic phase was dried over anhydrous magnesium sulfate, and the organic solvent was distilled off under reduced pressure. The organic solvent was purified by chromatography using methylene chloride as the eluent. 18.35 g of dimethyl ‘-diiodo-4,4’-diphthalate, that is, compound a, with a yield of 85.1% (based on dimethyl diphthalate)., 787-70-2

787-70-2 [1,1′-Biphenyl]-4,4′-dicarboxylic acid 13084, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Tongji University; Zhang Ronghua; Liu Changwei; Li Liangchun; (9 pag.)CN110483333; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI